Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $43.42, moving -1.83% from the previous trading session. CRISPR Therapeutics (CRSP) saw its shares surge in the last session ...

Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

BizTimes Media’s 24th annual Economic Trends event on Thursday featured insights and predictions from an economist, local business leaders and an academic ...

Vertex and CRISPR Therapeutics have won the backing ... a few months after turning it down for sickle cell disease. Final draft guidance published this morning clears Casgevy (exagamglogene ...

CRISPR and Vertex's two phase 1/2 studies in thalassaemia and SCD – called CLIMB-111 and CLIMB-211, respectively – have now recruited 19 patients. They are due to enrol 45 apiece, and are ...